insomnia
Five Facts about sleep and mental health
August 3, 2025Medical Communications Five Facts, Psychiatry, insomnia, mental health, sleep, sleep disorders, sleep health
1 Rapid Eye Movement (REM) sleep enhances creative thinking and helps the brain form connections between ideas, supporting mental wellbeing …
Minerva’s insomnia treatment beats Ambien in Phase 2b trial
June 25, 2019Manufacturing and Production MDD, Minerva Neurosciences, Placebo, ambien, insomnia, pharma, zolpidem
Massachusetts-based firm Minerva Neurosciences has announced that its sleeping pill seltorexant beat both Sanofi’s Ambien (zolpidem) and placebo in treating …
Ambien and other insomnia meds to be labelled with black box warnings after sleepwalking deaths
May 2, 2019Medical Communications, Research and Development FDA, ambien, black box warning, insomnia, sleeping pills, warning label
The FDA has said that Ambien, and other insomnia medications, must be labelled with a ‘black box warning’ – the …
Eisai and Purdue reveal positive Phase 3 data in insomnia
February 7, 2019Research and Development Eisai, Purdue Pharma, insomnia, lemborexant, pharma
Partners Eisai and Purdue Pharma have lifted the curtain on Phase 3 clinical data on their jointly developed therapy lemborexant …
Merck releases insomnia drug in US
February 4, 2015Sales and Marketing FDA, Merck, belsomra, insomnia, orexin, suvorexant
Merck’s insomnia drug Belsomra is now available in the US to treat patients who have difficulty falling asleep or staying …
FDA experts recommend Merck sleep pill
May 24, 2013Research and Development, Sales and Marketing FDA, Merck, insomnia, suvorexant
Merck received welcome news this week from the FDA after one of the US regulator’s expert groups voted to approve …
Merck releases new Phase III insomnia data
September 11, 2012Research and Development, Sales and Marketing Merck, insomnia, suvorexant
Merck says it is on course to file its investigational insomnia drug suvorexant in the US by the end of …
Merck’s sleep aid drug meets goals
June 15, 2012Research and Development, Sales and Marketing FDA, Merck, insomnia, sleep disorder, suvorexant
Merck’s novel insomnia drug suvorexant has improved patients’ ability to fall asleep, according to new data from two Phase III …
Merck prepares insomnia candidate
February 7, 2012Sales and Marketing Merck, insomnia
Merck is to file its new insomnia drug suvorexant, with US regulators later this year. Suvorexant is an orexin receptor …
GSK and Actelion drop insomnia treatment
January 30, 2011Research and Development Actelion, GSK, insomnia
Actelion and GlaxoSmithKline are to abandon development of phase III insomnia drug almorexant because of problems with side-effects.Almorexant a dual …
GSK signs $1.5 billion insomnia collaboration
July 16, 2008Sales and Marketing Actelion, GSK, insomnia
GlaxoSmithKline has joined forces with Swiss biopharmaceutical company Actelion to bring a new insomnia treatment to market.The deal could be …
